ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report

Arterioscler Thromb Vasc Biol. 2021 May 5;41(5):1753-1759. doi: 10.1161/ATVBAHA.120.315204. Epub 2021 Mar 11.

Abstract

[Figure: see text].

Trial registration: ClinicalTrials.gov NCT04722068.

Keywords: angiopoietin-like protein; cholesterol, LDL; familial hypercholesterolemia; isotope; leucine; lipoprotein.

Publication types

  • Clinical Study
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angiopoietin-Like Protein 3
  • Angiopoietin-like Proteins / antagonists & inhibitors*
  • Angiopoietin-like Proteins / metabolism
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / therapeutic use*
  • Apolipoprotein B-100 / blood*
  • Biomarkers / blood
  • Cholesterol, LDL / blood*
  • Female
  • Genetic Predisposition to Disease
  • Homozygote
  • Humans
  • Hyperlipoproteinemia Type II / blood
  • Hyperlipoproteinemia Type II / diagnosis
  • Hyperlipoproteinemia Type II / drug therapy*
  • Hyperlipoproteinemia Type II / genetics
  • Lipoproteins, IDL / blood*
  • Lipoproteins, LDL / blood*
  • Liver / drug effects*
  • Liver / metabolism
  • Male
  • Mutation
  • Netherlands
  • Pennsylvania
  • Phenotype
  • Receptors, LDL / genetics
  • Receptors, LDL / metabolism
  • Time Factors
  • Treatment Outcome

Substances

  • ANGPTL3 protein, human
  • APOB protein, human
  • Angiopoietin-Like Protein 3
  • Angiopoietin-like Proteins
  • Antibodies, Monoclonal
  • Anticholesteremic Agents
  • Apolipoprotein B-100
  • Biomarkers
  • Cholesterol, LDL
  • LDLR protein, human
  • Lipoproteins, IDL
  • Lipoproteins, LDL
  • Receptors, LDL
  • evinacumab

Associated data

  • ClinicalTrials.gov/NCT04722068